日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

新辅助维杜托利莫德联合纳武利尤单抗治疗高危可切除黑色素瘤:一项前瞻性 II 期试验

Diwakar Davar ,Robert M Morrison ,Amiran K Dzutsev ,Arivarasan Karunamurthy ,Joe-Marc Chauvin ,Florent Amatore ,Julie S Deutsch ,Rodrigo X Das Neves ,Richard R Rodrigues ,John A McCulloch ,Hong Wang ,Douglas J Hartman ,Jonathan H Badger ,Miriam R Fernandes ,Yulong Bai ,Jie Sun ,Alicia M Cole ,Poonam Aggarwal ,Jennifer R Fang ,Christopher Deitrick ,Riyue Bao ,Umamaheswar Duvvuri ,Shaum S Sridharan ,Seungwon W Kim ,Haroon A Choudry ,Matthew P Holtzman ,James F Pingpank ,James Patrick O'Toole ,Richelle DeBlasio ,Yang Jin ,Quanquan Ding ,Wentao Gao ,Christopher Groetsch ,Ornella Pagliano ,Amy Rose ,Corey Urban ,Jagjit Singh ,Prajan Divarkar ,David Mauro ,Dmitri Bobilev ,James Wooldridge ,Arthur M Krieg ,Matthew G Fury ,Jeffrey R Whiteaker ,Lei Zhao ,Amanda G Paulovich ,Yana G Najjar ,Jason J Luke ,John M Kirkwood ,Janis M Taube ,Hyun Jung Park ,Giorgio Trinchieri ,Hassane M Zarour

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

PD-1 和 LAG-3 靶向双特异性分子替博替利单抗在实体瘤和血液系统癌症中的应用:1 期临床试验

Jason J Luke, Manish R Patel, George R Blumenschein, Erika Hamilton, Bartosz Chmielowski, Susanna V Ulahannan, Roisin M Connolly, Cesar A Santa-Maria, Jie Wang, Shakeela W Bahadur, Andrew Weickhardt, Adam S Asch, Girish Mallesara, Philip Clingan, Monika Dlugosz-Danecka, Monika Tomaszewska-Kiecana, H

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

阿扎胞苷、依帕卡司他和帕博利珠单抗治疗晚期实体肿瘤的 I/II 期测序研究

Jason J Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing2

Tumor cell p38 inhibition to overcome immunotherapy resistance

肿瘤细胞 p38 抑制可克服免疫疗法耐药性

Jason J Luke, Rebekah E Dadey, Ryan C Augustin, Sarah Newman, Krishna B Singh, Rose Doerfler, Sarah Behr, Patrice Lee, Brian Isett, Christopher Deitrick, Aofei Li, Marion Joy, Carly Reeder, Katelyn Smith, Julie Urban, Lorenzo Sellitto, Mark Jelinek, Susan M Christner, Jan H Beumer, Liza C Villaruz, 

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

探索伊他替尼联合依帕卡司他或帕沙克利布治疗晚期实体瘤的安全性、对肿瘤微环境的影响及疗效:一项 I 期研究

Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, Patricia M LoRusso, Ignacio Garrido-Laguna, Lance Leopold, Ryan Geschwindt, Kai Ding, Michael Smith, Jordan D Berlin2

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

使用 CpG-A Toll 样受体 9 激动剂 Vidutolimod 治疗转移性黑色素瘤患者,克服 PD-1 阻断耐药性

Antoni Ribas, Theresa Medina, John M Kirkwood, Yousef Zakharia, Rene Gonzalez, Diwakar Davar, Bartosz Chmielowski, Katie M Campbell, Riyue Bao, Heather Kelley, Aaron Morris, David Mauro, James E Wooldridge, Jason J Luke, George J Weiner, Arthur M Krieg, Mohammed M Milhem

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma

肿瘤微环境的免疫基因组决定因素与高危神经母细胞瘤的较高生存率相关

Riyue Bao, Stefani Spranger, Kyle Hernandez, Yuanyuan Zha, Peter Pytel, Jason J Luke, Thomas F Gajewski, Samuel L Volchenboum, Susan L Cohn, Ami V Desai

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

转移性葡萄膜黑色素瘤生存的转录分析提名NRP1作为治疗靶点

Riyue Bao, Oliver Surriga, Daniel J Olson, Jacob B Allred, Carrie A Strand, Yuanyuan Zha, Timothy Carll, Brian W Labadie, Bruno R Bastos, Marcus Butler, David Hogg, Elgilda Musi, Grazia Ambrosini, Pamela Munster, Gary K Schwartz, Jason J Luke

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

腺苷2A受体阻断作为难治性肾细胞癌的免疫疗法

Lawrence Fong ,Andrew Hotson ,John D Powderly ,Mario Sznol ,Rebecca S Heist ,Toni K Choueiri ,Saby George ,Brett G M Hughes ,Matthew D Hellmann ,Dale R Shepard ,Brian I Rini ,Shivaani Kummar ,Amy M Weise ,Matthew J Riese ,Ben Markman ,Leisha A Emens ,Daruka Mahadevan ,Jason J Luke ,Ginna Laport ,Joshua D Brody ,Leonel Hernandez-Aya ,Philip Bonomi ,Jonathan W Goldman ,Lyudmyla Berim ,Daniel J Renouf ,Rachel A Goodwin ,Brian Munneke ,Po Y Ho ,Jessica Hsieh ,Ian McCaffery ,Long Kwei ,Stephen B Willingham ,Richard A Miller

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

PD-1 指导的 CTLA-4 阻断双特异性 DART 分子的开发和初步临床活性

Alexey Berezhnoy ,Bradley J Sumrow ,Kurt Stahl ,Kalpana Shah ,Daorong Liu ,Jonathan Li ,Su-Shin Hao ,Anushka De Costa ,Sanjeev Kaul ,Johanna Bendell ,Gregory M Cote ,Jason J Luke ,Rachel E Sanborn ,Manish R Sharma ,Francine Chen ,Hua Li ,Gundo Diedrich ,Ezio Bonvini ,Paul A Moore